Navigation Links
Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
Date:3/21/2011

RICHMOND, Va., March 21, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung infections has been cleared by the U.S. Food and Drug Administration (FDA).  

In 2010, Insmed initially submitted a regulatory filing to FDA requesting clearance to proceed with a Phase 2 clinical trial for ARIKACE in NTM.  FDA responded by suggesting that the Company could change the proposed Phase 2 trial to a primary efficacy study.  Based on this feedback, Insmed submitted its IND seeking FDA clearance to initiate a Phase 3 clinical trial of ARIKACE in NTM earlier in the first quarter of this year.

Development of the clinical program aimed at NTM infections was done in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health.  According to Kenneth Oliver, M.D., M.P.H., staff pulmonologist in the NIAID Laboratory of Clinical Infectious Diseases, current NTM treatment requires lengthy multi-drug regimens that can be poorly tolerated and are often not very effective, especially in patients with severe disease or in those who have failed prior treatment attempts.

No new drugs have been assessed for NTM in a significant number of years. The sustained-release formulation of ARIKACE allows for targeting of the drug to the lungs and the site of disease.

"FDA clearance of our IND to conduct a pivotal Phase 3 clinical trial for ARIKACE in NTM is a critical step in continuing to advance our development plan for this compound," said Renu Gupta, M.D., Executive Vice President Development & Chief Medical Officer of Insmed.  "We continue to expect that patient accrual will begin in our Phase 3 clinical trials of ARIKACE in NT
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Insmed to Host Second Quarter 2009 Conference Call
3. Insmed Announces Addition to the Russell 3000(R) Index
4. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
5. Insmed CEO Resigns Due to Health Concerns
6. Insmed Announces First Quarter 2009 Financial Results
7. Insmed Regains NASDAQ Compliance
8. Insmed to Host First Quarter 2009 Conference Call
9. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
10. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
11. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 ... from Sartorius, A & D Weighing, Rice Lake, ... CPA Semi-Micro Balance . The Sartorius CPA Semi-Micro ... an affordable high-quality, precise, and user-friendly laboratory balance. ... of laboratory equipment, their laboratory balances are well ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... 23, 2011 The Clearity Foundation , ... information to women with ovarian cancer, today announced ... a new position for the organization. The Executive ... as it increases its capacity to support more ...
... At least one dengue vaccine could be licensed within ... the development process for multiple dengue vaccine candidates in ... the necessary testing, clinical trial design, and licensure, a ... number of important issues have been identified for regulatory ...
... from North Carolina State University have developed a ... in microfluidic devices, by using liquid metal. Microfluidic ... a wide variety of applications, from testing minute ... "By making it easier to incorporate electrodes into ...
Cached Biology Technology:The Clearity Foundation Hires Hillary Theakston as Executive Director 2The Clearity Foundation Hires Hillary Theakston as Executive Director 3Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines 2Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines 3Liquid metal key to simpler creation of electrodes for microfluidic devices 2
(Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
(Date:10/16/2014)... women experienced improvements in vaginal atrophy, with no ... after 12 weeks of daily 10 milligram (mg) ... supplement previously shown to help relieve certain menopause ... reported in a poster at the North American ... "These data documented improved vaginal epithelium, without significant ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... 2012  The board of directors of Westlake Chemical Corporation (NYSE: ... 18.75 cents per share, an increase of over 150% from ... of 2012. The increased dividend will be payable on September 12, ... This is the 32nd successive quarterly dividend that Westlake ...
... the size of their poison glands to potential predators, finds ... Frontiers in Zoology . The brighter the colour, the ... different animals to warn potential predators that they are poisonous. ... which predators quickly learn to avoid. Paper wasps have conspicuous ...
... certain disease mechanisms, illness progression and response to new ... such as nematodes, fruit flies or zebra fish. ... of many individual animals to detect mutants worthy of ... system that uses artificial intelligence and cutting-edge image processing ...
Cached Biology News:Artificial intelligence helps detect subtle differences in mutant worms 2Artificial intelligence helps detect subtle differences in mutant worms 3Artificial intelligence helps detect subtle differences in mutant worms 4
... DNA polymerase is an antibody-mediated ... both conventional and real-time PCR ... at a concentration of 5 ... 250 units polymerase, 1.25 ml ...
MAb to Mouse MHC Class I H-2Kd...
... GELase™ Agarose Gel-Digesting Preparation contains a ... for simple, quantitative recovery of intact DNA ... agarose gels following electrophoresis in TAE, TBE, ... be digested directly in the TAE, TBE, ...
... GELase™ Agarose Gel-Digesting Preparation contains a unique ... simple, quantitative recovery of intact DNA and ... gels following electrophoresis in TAE, TBE, MOPS, ... digested directly in the TAE, TBE, MOPS, ...
Biology Products: